|
Schizophrenia
|
0.350 |
Biomarker
|
disease |
BEFREE |
Despite a slight difference persisting in the meta-analysis carried out using four European populations, these data suggest, altogether, that UHMK1 does not play a major role in susceptibility to schizophrenia.
|
21399567 |
2011 |
|
Schizophrenia
|
0.350 |
Biomarker
|
disease |
PSYGENET |
Despite a slight difference persisting in the meta-analysis carried out using four European populations, these data suggest, altogether, that UHMK1 does not play a major role in susceptibility to schizophrenia.
|
21399567 |
2011 |
|
Schizophrenia
|
0.350 |
Biomarker
|
disease |
PSYGENET |
Hence, these data do not provide support for the hypothesis that altered expression is the mechanism by which genetic variation of KIS may increase susceptibility to schizophrenia, nor evidence that KIS expression is altered in the disease itself, at least in terms of the parameters studied here.
|
19747464 |
2009 |
|
Schizophrenia
|
0.350 |
GeneticVariation
|
disease |
BEFREE |
Of these, four contained or neighboured genes associated with schizophrenia (NOS1AP/UHMK1, ATF2, NSF and PIK3C3).
|
19451863 |
2009 |
|
Schizophrenia
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
Hence, these data do not provide support for the hypothesis that altered expression is the mechanism by which genetic variation of KIS may increase susceptibility to schizophrenia, nor evidence that KIS expression is altered in the disease itself, at least in terms of the parameters studied here.
|
19747464 |
2009 |
|
Schizophrenia
|
0.350 |
Biomarker
|
disease |
LHGDN |
The finding of allelic association with markers in the UHMK1 gene might help explain why it has not been possible, despite great effort, to satisfactorily confirm previously reported associations between schizophrenia and the genes RGS4 and NOS1AP/CAPON.
|
18414510 |
2008 |
|
Schizophrenia
|
0.350 |
GeneticVariation
|
disease |
BEFREE |
The finding of allelic association with markers in the UHMK1 gene might help explain why it has not been possible, despite great effort, to satisfactorily confirm previously reported associations between schizophrenia and the genes RGS4 and NOS1AP/CAPON.
|
18414510 |
2008 |
|
Schizophrenia
|
0.350 |
Biomarker
|
disease |
PSYGENET |
The finding of allelic association with markers in the UHMK1 gene might help explain why it has not been possible, despite great effort, to satisfactorily confirm previously reported associations between schizophrenia and the genes RGS4 and NOS1AP/CAPON.
|
18414510 |
2008 |
|
Schizophrenia
|
0.350 |
Biomarker
|
disease |
BEFREE |
These results provide preliminary evidence that the UHMK1 gene increases susceptibility to schizophrenia.
|
16978587 |
2007 |
|
Schizophrenia
|
0.350 |
Biomarker
|
disease |
LHGDN |
These results provide preliminary evidence that the UHMK1 gene increases susceptibility to schizophrenia.
|
16978587 |
2007 |
|
Schizophrenia
|
0.350 |
Biomarker
|
disease |
PSYGENET |
These results provide preliminary evidence that the UHMK1 gene increases susceptibility to schizophrenia.
|
16978587 |
2007 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Aid by the BBB-permeable properties, KIST-G1 (5 mg/kg) suppressed glioblastoma cell growth and migration almost completely in the brain of glioblastoma xenograft models by showing 98.2 ± 0.1% reduced tumor area compared with phosphate buffered saline (PBS)-injected control.
|
31569420 |
2019 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
On the other hand, the KIS gene was overexpressed in NF1-associated plexiform neurofibromas and malignant peripheral nerve sheath tumors (MPNSTs) as compared to dermal neurofibroma which suggests a possible implication of KIS in the genesis of NF1-associated tumors.
|
12782393 |
2003 |
|
Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
For comparison we have analyzed PAX-5 expression in another B-cell lymphoma, KIS-1, indicating that transcription from the distal PAX-5 promoter was increased in this tumor in agreement with the previously characterized translocation of the immunoglobulin Emicro; enhancer adjacent to PAX-5 exon 1A.
|
9808580 |
1998 |
|
Diffuse Large B-Cell Lymphoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
KIS-1 cell line was established from a patient with diffuse large cell lymphoma of B-cell type carrying t(9;14).
|
9722295 |
1998 |
|
Adult Diffuse Large Cell Lymphoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
KIS-1 cell line was established from a patient with diffuse large cell lymphoma of B-cell type carrying t(9;14).
|
9722295 |
1998 |
|
Childhood Diffuse Large Cell Lymphoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
KIS-1 cell line was established from a patient with diffuse large cell lymphoma of B-cell type carrying t(9;14).
|
9722295 |
1998 |
|
Diffuse Large B-Cell Lymphoma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
When compared with six other DLCL cell lines lacking t(9;14)(p13;q32), the KIS-1 cell line showed an 11-fold overexpression of PAX-5 mRNA and a significantly reduced expression of the p53 gene, which is normally regulated by PAX-5.
|
8943844 |
1996 |
|
Adult Diffuse Large Cell Lymphoma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
When compared with six other DLCL cell lines lacking t(9;14)(p13;q32), the KIS-1 cell line showed an 11-fold overexpression of PAX-5 mRNA and a significantly reduced expression of the p53 gene, which is normally regulated by PAX-5.
|
8943844 |
1996 |
|
Childhood Diffuse Large Cell Lymphoma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
When compared with six other DLCL cell lines lacking t(9;14)(p13;q32), the KIS-1 cell line showed an 11-fold overexpression of PAX-5 mRNA and a significantly reduced expression of the p53 gene, which is normally regulated by PAX-5.
|
8943844 |
1996 |
|
Diffuse Large B-Cell Lymphoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
KIS-1 is the only known B-cell line derived from Ki-1-positive diffuse large cell lymphoma, and should be useful for defining the biological implications of Ki-1 antigen.
|
2852183 |
1988 |
|
Adult Diffuse Large Cell Lymphoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
KIS-1 is the only known B-cell line derived from Ki-1-positive diffuse large cell lymphoma, and should be useful for defining the biological implications of Ki-1 antigen.
|
2852183 |
1988 |
|
Childhood Diffuse Large Cell Lymphoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
KIS-1 is the only known B-cell line derived from Ki-1-positive diffuse large cell lymphoma, and should be useful for defining the biological implications of Ki-1 antigen.
|
2852183 |
1988 |
|
Brain Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Our results demonstrate the effectiveness of an aryloxazole moiety in targeting brain tumors and suggest KIST-G1 as a potent anti-glioblastoma agent.
|
31569420 |
2019 |
|
Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Aid by the BBB-permeable properties, KIST-G1 (5 mg/kg) suppressed glioblastoma cell growth and migration almost completely in the brain of glioblastoma xenograft models by showing 98.2 ± 0.1% reduced tumor area compared with phosphate buffered saline (PBS)-injected control.
|
31569420 |
2019 |